Studies of treatment of non-traumatic intracranial hemorrhage in newborn infants

新生儿非外伤性颅内出血的治疗研究

基本信息

批准号：
61570479
负责人：
SHIRAHATA Akira
金额：
$ 1.41万
依托单位：
University of Occupational and Environmental Health, Japan
依托单位国家：
日本
项目类别：
Grant-in-Aid for General Scientific Research (C)
财政年份：
1986
资助国家：
日本
起止时间：
1986 至 1988
项目状态：
已结题

项目摘要

1) Coagulation studies were carried out in 65 newborn infants with non-traumatic intracranial hemorrhage. Based on the findings of coagulation status, it was estimated that 31 out of 65 neonates were suffered from DIC and/or primary hemorrhagic disease of the newborn. Mortality of the cases with coagualtion abnormalities was significantly higher than that of cases without coagulation abnormalities.2) Next study was carried out in order to clarify the effects of gabexate mesilate(FOY) and antithrombin III concentrates on DIC of newborn infants. FOY was superior to heparin in improvement of clinical findings of DIC, although no difference was seen in changes of loboratory findings on hemostasis between the patient group treated with FOY alone and the other treatment groups. Those results indicated that the administration of FOY was more effective than haparin therapy for the DIC of newborn infants. Furthermore, a combination therapy of FOY and antithrombin III concentrates is effective for the DIC in newborn infants in whom administration of FOY alone was not effective.3) We administered factor XIII concentrate to premature infants within 6 hours of age to examine its effectiveness in reducing the incidence of severe intracranial hemorrhage. Seven(29%) out of 24 control infants sustained intraventricular hemorrhage, and 3(13%) of 24 infants receiving the treatment did. Incidence of severe intraventricular hemorrhage in treated and control infants with high risk for intraventricular hemorrhage was 20% and 83% respectively. Factor XIII concentrate appears to have a beneficial effects on the prevention of intraventricular hemorrhage in premature infants.

1）在65名非创伤性颅内出血的新生婴儿中进行了凝血研究。根据凝血状态的发现，估计有65名新生儿中有31例患有新生儿的DIC和/或原发性出血性疾病。凝结异常的病例的死亡率显着高于没有凝血异常的病例。2）下一项研究是为了澄清甘证酸中酸盐（FOY）（FOY）和抗黑素III浓度对新生婴儿DIC的影响。 FOY在改善DIC的临床发现方面比肝素优于肝素，尽管在单独用Foy和其他治疗组治疗的患者组之间对止血的发现变化中没有差异。这些结果表明，在新生婴儿的DIC中，FOY的给药比Haparin疗法更有效。此外，FOY和抗凝血酶III浓缩物的联合疗法对新生儿的DIC有效，在新生儿中，它们仅由Foy进行给药。3）我们将XIII浓缩液用于6个小时的年龄较大的早产儿，以检查其在降低严重内部颅内血液高位的发生率方面的有效性。在24名对照婴儿中，有7名（29％）持续脑室出血，接受治疗的24名婴儿中有3例（13％）确实发生了。脑室内出血风险高的治疗和对照婴儿严重脑室出血的发生率分别为20％和83％。因子XIII浓缩物似乎对预防早产婴儿的脑室内出血有有益的作用。